Agonistic antibodies reveal the function of GPR56 in human glioma U87-MG cells.

Research paper by Shigeyuki S Ohta, Sayaka S Sakaguchi, Yuki Y Kobayashi, Norikazu N Mizuno, Kenji K Tago, Hiroshi H Itoh

Indexed on: 04 Apr '15Published on: 04 Apr '15Published in: Biological & pharmaceutical bulletin


GPR56 is a member of the adhesion G protein-coupled receptor (GPCR) and is highly expressed in parts of tumor cells. The involvement of GPR56 in tumorigenesis has been reported. We generated agonistic monoclonal antibodies against human GPR56 and analyzed the action and signaling pathway of GPR56. The antibodies inhibited cell migration through the Gq and Rho pathway in human glioma U87-MG cells. Co-immunoprecipitation analysis indicated that the interaction between the GPR56 extracellular domain and transmembrane domain was potentiated by agonistic antibodies. These results demonstrated that functional antibodies are invaluable tools for GPCR research and should open a new avenue for therapeutic treatment of tumors.